Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson 4Q

Worldwide Pharmaceutical sales were $22.5 billion for the year (-8%), while Worldwide Medical Devices and Diagnostics sales were $23.6 billion for year (+2%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 4Q

4Q Revenues: $16.6 billion (+9%)

4Q Earnings: $2.2 billion (-19%)

FY Revenues: $61.9 billion (-3%)

FY Earnings: $12.3 billion (-5%)

Comments: Worldwide Pharmaceutical sales were $22.5 billion for the year (-8%), while Worldwide Medical Devices and Diagnostics sales were $23.6 billion for year (+2%). Products with operational growth for the year included: Remicade, Prezista, Velcade, Risperdal, Consta. Sales of Topamax and Risperdal were negatively impacted by generic competition. U.S. Pharma sales were down 3% in 4Q09 to $3.3 billion, and were down 12% in FY09 to $13 billion. Worldwide Consumer sales were $15.8 billion for the year (-2%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters